These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36211376)

  • 1. Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.
    Haas Q; Markov N; Muerner L; Rubino V; Benjak A; Haubitz M; Baerlocher GM; Ng CKY; Münz C; Riether C; Ochsenbein AF; Simon HU; von Gunten S
    Front Immunol; 2022; 13():996746. PubMed ID: 36211376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
    Bärenwaldt A; Läubli H
    Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
    [No Abstract]   [Full Text] [Related]  

  • 3. Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
    Benmerzoug S; Chevalier MF; Verardo M; Nguyen S; Cesson V; Schneider AK; Dartiguenave F; Rodrigues-Dias SC; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
    Eur Urol Focus; 2022 May; 8(3):748-751. PubMed ID: 34147404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
    Vuchkovska A; Glanville DG; Scurti GM; Nishimura MI; White P; Ulijasz AT; Iwashima M
    Immunology; 2022 Jun; 166(2):238-248. PubMed ID: 35290663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
    van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
    Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
    Boelaars K; van Kooyk Y
    Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siglec Signaling in the Tumor Microenvironment.
    van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
    Front Immunol; 2021; 12():790317. PubMed ID: 34966391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Siglec-9 Regulates an Effector Memory CD8
    Haas Q; Boligan KF; Jandus C; Schneider C; Simillion C; Stanczak MA; Haubitz M; Seyed Jafari SM; Zippelius A; Baerlocher GM; Läubli H; Hunger RE; Romero P; Simon HU; von Gunten S
    Cancer Immunol Res; 2019 May; 7(5):707-718. PubMed ID: 30988027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer.
    Lv K; Sun M; Fang H; Wang J; Lin C; Liu H; Zhang H; Li H; He H; Gu Y; Li R; Shao F; Xu J
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting glyco-immune checkpoints for cancer therapy.
    Manni M; Läubli H
    Expert Opin Biol Ther; 2021 Aug; 21(8):1063-1071. PubMed ID: 33502268
    [No Abstract]   [Full Text] [Related]  

  • 11. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
    Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
    Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9.
    Chan C; Lustig M; Jansen JHM; Garcia Villagrasa L; Raymakers L; Daamen LA; Valerius T; van Tetering G; Leusen JHW
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Siglec-G Suppresses CD8
    Yin S; Li C; Shen X; Yu G; Cui L; Wu Y; He Y; Yu S; Chen J; Lu S; Qiu G; Song M; Qian C; Zou Z; Yu Y; Xu S
    Adv Sci (Weinh); 2024 Dec; 11(45):e2403438. PubMed ID: 39373395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activation.
    Stewart N; Daly J; Drummond-Guy O; Krishnamoorthy V; Stark JC; Riley NM; Williams KC; Bertozzi CR; Wisnovsky S
    J Biol Chem; 2024 Feb; 300(2):105579. PubMed ID: 38141764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
    Adams OJ; Stanczak MA; von Gunten S; Läubli H
    Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siglec receptors as new immune checkpoints in cancer.
    Stanczak MA; Läubli H
    Mol Aspects Med; 2023 Apr; 90():101112. PubMed ID: 35948467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias.
    Virgo P; Denning-Kendall PA; Erickson-Miller CL; Singha S; Evely R; Hows JM; Freeman SD
    Br J Haematol; 2003 Nov; 123(3):420-30. PubMed ID: 14617000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity.
    Huang J; Li M; Mei B; Li J; Zhu Y; Guo Q; Huang J; Zhang G
    J Transl Med; 2022 Oct; 20(1):496. PubMed ID: 36316782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sialoglycan-Siglec-E checkpoint axis in dexamethasone-induced immune subversion in glioma-microglia transwell co-culture system.
    Wielgat P; Czarnomysy R; Trofimiuk E; Car H
    Immunol Res; 2019 Oct; 67(4-5):348-357. PubMed ID: 31741237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
    Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
    Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.